Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Stavudine
Drug ID BADD_D02068
Description A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.
Indications and Usage For the treatment of human immunovirus (HIV) infections.
Marketing Status approved; investigational
ATC Code J05AF04
DrugBank ID DB00649
KEGG ID D00445
MeSH ID D018119
PubChem ID 18283
TTD Drug ID D0Z8EX
NDC Product Code 65015-672; 65862-342; 68554-0015; 65862-263; 53104-0111; 65015-795; 68554-0045
UNII BO9LE4QFZF
Synonyms Stavudine | D4T | 2',3'-Didehydro-3'-deoxythymidine | 2',3' Didehydro 3' deoxythymidine | 2',3'-Didehydro-2',3'-dideoxythmidine | Zerit | BMY-27857 | BMY 27857 | BMY27857 | Stavudine, Monosodium Salt
Chemical Information
Molecular Formula C10H12N2O4
CAS Registry Number 3056-17-5
SMILES CC1=CN(C(=O)NC1=O)C2C=CC(O2)CO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Fungal infection11.03.05.001--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Guillain-Barre syndrome11.07.01.001; 17.09.01.001; 10.04.10.005--
Gynaecomastia21.05.04.003; 05.05.02.003--
Haematuria24.07.01.047; 20.02.01.006; 21.10.01.018--
Haemoglobin decreased13.01.05.003--Not Available
Headache17.14.01.001--
Hepatic failure09.01.03.002--
Hepatic function abnormal09.01.02.001--Not Available
Hepatic steatosis14.08.04.005; 09.01.07.003--Not Available
Hepatitis09.01.07.004--Not Available
Hepatitis B11.05.28.003; 09.01.09.003--
Hepatocellular injury09.01.07.008--Not Available
Hepatomegaly09.01.05.001--Not Available
Hepatotoxicity12.03.01.008; 09.01.07.009--Not Available
Hyperbilirubinaemia01.06.04.003; 14.11.01.010; 09.01.01.003--Not Available
Hypercholesterolaemia14.08.01.001--Not Available
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperlactacidaemia14.01.01.0060.000565%Not Available
Hypersensitivity10.01.03.003--
Hypertriglyceridaemia14.08.02.001--
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Influenza11.05.03.001; 22.07.02.001--Not Available
Injury12.01.08.004--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Insulin resistance14.06.02.003; 05.06.02.003--Not Available
Jaundice09.01.01.004; 01.06.04.004; 23.03.03.030--Not Available
Lactic acidosis14.01.01.0020.000988%Not Available
The 2th Page    First    Pre   2 3 4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene